Work

Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.354

Authors: Alicia K. Morgans, Maelys Touya, Nader N. El-Chaar, Dina Elsouda, Krishnan Ramaswamy, Kelechi L. Adejumo, Danielle Gentile, Bruce A. Feinberg, Parisa Asgarisabet, Prathamesh Pathak, Stephen J. Freedland

Institutions: Dana-Farber Cancer Institute, Astellas Pharma (United States), Pfizer (United States), Cardinal Health (United States), Cedars-Sinai Medical Center, Durham VA Medical Center

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4407698042

Cites:

Cited by:

Related to: 10